SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

NeuBase Therapeutics, Inc. – ‘10-K’ for 9/30/13 – ‘EX-101.CAL’

On:  Friday, 12/27/13, at 4:06pm ET   ·   For:  9/30/13   ·   Accession #:  1387131-13-4795   ·   File #:  1-35963

Previous ‘10-K’:  ‘10-K’ on 1/9/13 for 9/30/12   ·   Next:  ‘10-K’ on 12/22/14 for 9/30/14   ·   Latest:  ‘10-K’ on 12/21/22 for 9/30/22

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

12/27/13  NeuBase Therapeutics, Inc.        10-K        9/30/13   49:4.7M                                   Quality EDGAR So… LLC/FA

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    554K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     22K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     22K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     17K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     17K 
48: R1          Document and Entity Information                     HTML     44K 
35: R2          Balance Sheets                                      HTML     79K 
32: R3          Balance Sheets (Parenthetical)                      HTML     37K 
14: R4          Statements of Operations                            HTML     84K 
34: R5          Statements of Operations (Parenthetical)            HTML     18K 
24: R6          Statements of Stockholders' Equity                  HTML     99K 
42: R7          Statements of Cash Flows                            HTML    136K 
25: R8          Description of Business                             HTML     19K 
27: R9          Summary of Significant Accounting Policies          HTML     49K 
15: R10         Patent Costs                                        HTML     20K 
26: R11         Notes Payable                                       HTML     21K 
41: R12         Derivative Liability and Fair Value Measurements    HTML     32K 
38: R13         Capital Stock                                       HTML     43K 
33: R14         Common Stock Warrants                               HTML     76K 
45: R15         Common Stock Options                                HTML     38K 
40: R16         Commitments and Contingencies                       HTML     21K 
12: R17         Subsequent Events                                   HTML     19K 
17: R18         Summary of Significant Accounting Policies          HTML     92K 
                (Policies)                                                       
44: R19         Summary of Significant Accounting Policies          HTML     31K 
                (Tables)                                                         
47: R20         Common Stock Warrants (Tables)                      HTML     66K 
49: R21         Common Stock Options (Tables)                       HTML     32K 
46: R22         Description of Business (Details Narrative)         HTML     21K 
37: R23         Summary of Significant Accounting Policies          HTML     37K 
                (Details Narrative)                                              
16: R24         Summary of Significant Accounting Policies          HTML     28K 
                (Details)                                                        
22: R25         Summary of Significant Accounting Policies          HTML     24K 
                (Details1)                                                       
19: R26         Patent Costs (Details Narrative)                    HTML     25K 
18: R27         Notes Payable (Details Narrative)                   HTML     31K 
28: R28         Derivative Liability and Fair Value Measurements    HTML    112K 
                (Details Narrative)                                              
36: R29         Capital Stock (Details Narrative)                   HTML    130K 
39: R30         Common Stock Warrants (Details Narrative)           HTML    109K 
21: R31         Common Stock Warrants (Details)                     HTML     67K 
29: R32         Common Stock Options (Details Narrative)            HTML     57K 
43: R33         Common Stock Options (Details)                      HTML     44K 
20: R34         Subsequent Events (Details Narrative)               HTML     41K 
31: XML         IDEA XML File -- Filing Summary                      XML     67K 
13: EXCEL       IDEA Workbook of Financial Reports                  XLSX    121K 
30: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS    631K 
 6: EX-101.INS  XBRL Instance -- ohrp-20130930                       XML   1.26M 
 8: EX-101.CAL  XBRL Calculations -- ohrp-20130930_cal               XML     99K 
 9: EX-101.DEF  XBRL Definitions -- ohrp-20130930_def                XML    321K 
10: EX-101.LAB  XBRL Labels -- ohrp-20130930_lab                     XML    689K 
11: EX-101.PRE  XBRL Presentations -- ohrp-20130930_pre              XML    517K 
 7: EX-101.SCH  XBRL Schema -- ohrp-20130930                         XSD    113K 
23: ZIP         XBRL Zipped Folder -- 0001387131-13-004795-xbrl      Zip     91K

‘EX-101.CAL’   —   XBRL Calculations — ohrp-20130930_cal

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" standalone="no" encoding="windows-1252"?>
<!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 3.6c -->
<!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
<!-- Field: Doc-Info; Name: Source; Value: ohrp_09302013.xfr; Date: 2013%2D12%2D27T17:13:47 -->
<!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/DocumentAndEntityInformation" xlink:href="ohrp-20130930.xsd#DocumentAndEntityInformation" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/BalanceSheets" xlink:href="ohrp-20130930.xsd#BalanceSheets" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/BalanceSheetsParenthetical" xlink:href="ohrp-20130930.xsd#BalanceSheetsParenthetical" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/StatementsOfOperations" xlink:href="ohrp-20130930.xsd#StatementsOfOperations" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/StatementsOfOperationsParenthetical" xlink:href="ohrp-20130930.xsd#StatementsOfOperationsParenthetical" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/StatementsOfStockholdersEquity" xlink:href="ohrp-20130930.xsd#StatementsOfStockholdersEquity" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/StatementsOfCashFlows" xlink:href="ohrp-20130930.xsd#StatementsOfCashFlows" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/DescriptionOfBusiness" xlink:href="ohrp-20130930.xsd#DescriptionOfBusiness" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ohrp-20130930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/PatentCosts" xlink:href="ohrp-20130930.xsd#PatentCosts" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/NotesPayable" xlink:href="ohrp-20130930.xsd#NotesPayable" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/DerivativeLiabilityAndFairValueMeasurements" xlink:href="ohrp-20130930.xsd#DerivativeLiabilityAndFairValueMeasurements" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/CapitalStock" xlink:href="ohrp-20130930.xsd#CapitalStock" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/CommonStockWarrants" xlink:href="ohrp-20130930.xsd#CommonStockWarrants" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/CommonStockOptions" xlink:href="ohrp-20130930.xsd#CommonStockOptions" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/CommitmentsAndContingencies" xlink:href="ohrp-20130930.xsd#CommitmentsAndContingencies" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/SubsequentEvents" xlink:href="ohrp-20130930.xsd#SubsequentEvents" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ohrp-20130930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ohrp-20130930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/CommonStockWarrantsTables" xlink:href="ohrp-20130930.xsd#CommonStockWarrantsTables" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/CommonStockOptionsTables" xlink:href="ohrp-20130930.xsd#CommonStockOptionsTables" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/DescriptionOfBusinessDetailsNarrative" xlink:href="ohrp-20130930.xsd#DescriptionOfBusinessDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ohrp-20130930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="ohrp-20130930.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/SummaryOfSignificantAccountingPoliciesDetails1" xlink:href="ohrp-20130930.xsd#SummaryOfSignificantAccountingPoliciesDetails1" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/PatentCostsDetailsNarrative" xlink:href="ohrp-20130930.xsd#PatentCostsDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/NotesPayableDetailsNarrative" xlink:href="ohrp-20130930.xsd#NotesPayableDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/DerivativeLiabilityAndFairValueMeasurementsDetailsNarrative" xlink:href="ohrp-20130930.xsd#DerivativeLiabilityAndFairValueMeasurementsDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/CapitalStockDetailsNarrative" xlink:href="ohrp-20130930.xsd#CapitalStockDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/CommonStockWarrantsDetailsNarrative" xlink:href="ohrp-20130930.xsd#CommonStockWarrantsDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/CommonStockWarrantsDetails" xlink:href="ohrp-20130930.xsd#CommonStockWarrantsDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/CommonStockOptionsDetailsNarrative" xlink:href="ohrp-20130930.xsd#CommonStockOptionsDetailsNarrative" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/CommonStockOptionsDetails" xlink:href="ohrp-20130930.xsd#CommonStockOptionsDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://ohrpharmaceutical.com/role/SubsequentEventsDetailsNarrative" xlink:href="ohrp-20130930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash"/>
<link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent"/>
<link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaapGrantsReceivableCurrent"/>
<link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapGrantsReceivableCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent"/>
<link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets"/>
<link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet"/>
<link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="ohrp-20130930.xsd#ohrp_PatentCostsNet" xlink:label="loc_ohrpPatentCostsNet"/>
<link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_ohrpPatentCostsNet" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent"/>
<link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent"/>
<link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent"/>
<link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities"/>
<link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue"/>
<link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue"/>
<link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital"/>
<link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaapCommonStockShareSubscribedButUnissuedSubscriptionsReceivable"/>
<link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit"/>
<link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_us-gaapDevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/>
<link:calculationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapDevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity"/>
<link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1"/>
<link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense"/>
<link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense"/>
<link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees"/>
<link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages"/>
<link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit"/>
<link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1"/>
<link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense"/>
<link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaapGainLossOnDerivativeInstrumentsNetPretax"/>
<link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets"/>
<link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense"/>
<link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt"/>
<link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
<link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit"/>
<link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
<link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaapDiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
<link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="loc_us-gaapDiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss"/>
<link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1"/>
<link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Statements of Operations (Parenthetical)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/StatementsOfStockholdersEquity" xlink:title="00000006 - Statement - Statements of Stockholders' Equity"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Statements of Cash Flows">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="loc_us-gaapProceedsFromSaleOfProductiveAssets"/>
<link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfProductiveAssets" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment"/>
<link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets"/>
<link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaapProceedsFromDivestitureOfBusinesses"/>
<link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromDivestitureOfBusinesses" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
<link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity"/>
<link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises"/>
<link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt"/>
<link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt"/>
<link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable"/>
<link:calculationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable"/>
<link:calculationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt"/>
<link:calculationArc order="800" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" weight="-1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/DescriptionOfBusiness" xlink:title="00000008 - Disclosure - DESCRIPTION OF BUSINESS"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/PatentCosts" xlink:title="00000010 - Disclosure - PATENT COSTS"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/NotesPayable" xlink:title="00000011 - Disclosure - NOTES PAYABLE"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/DerivativeLiabilityAndFairValueMeasurements" xlink:title="00000012 - Disclosure - DERIVATIVE LIABILITY AND FAIR VALUE MEASUREMENTS"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/CapitalStock" xlink:title="00000013 - Disclosure - CAPITAL STOCK"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/CommonStockWarrants" xlink:title="00000014 - Disclosure - COMMON STOCK WARRANTS"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/CommonStockOptions" xlink:title="00000015 - Disclosure - COMMON STOCK OPTIONS"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - SUBSEQUENT EVENTS"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/CommonStockWarrantsTables" xlink:title="00000020 - Disclosure - COMMON STOCK WARRANTS (Tables)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/CommonStockOptionsTables" xlink:title="00000021 - Disclosure - COMMON STOCK OPTIONS (Tables)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/DescriptionOfBusinessDetailsNarrative" xlink:title="00000022 - Disclosure - DESCRIPTION OF BUSINESS (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/SummaryOfSignificantAccountingPoliciesDetails1" xlink:title="00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details1)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/PatentCostsDetailsNarrative" xlink:title="00000026 - Disclosure - PATENT COSTS (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/NotesPayableDetailsNarrative" xlink:title="00000027 - Disclosure - NOTES PAYABLE (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/DerivativeLiabilityAndFairValueMeasurementsDetailsNarrative" xlink:title="00000028 - Disclosure - DERIVATIVE LIABILITY AND FAIR VALUE MEASUREMENTS (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/CapitalStockDetailsNarrative" xlink:title="00000029 - Disclosure - CAPITAL STOCK (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/CommonStockWarrantsDetailsNarrative" xlink:title="00000030 - Disclosure - COMMON STOCK WARRANTS (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/CommonStockWarrantsDetails" xlink:title="00000031 - Disclosure - COMMON STOCK WARRANTS (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/CommonStockOptionsDetailsNarrative" xlink:title="00000032 - Disclosure - COMMON STOCK OPTIONS (Details Narrative)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/CommonStockOptionsDetails" xlink:title="00000033 - Disclosure - COMMON STOCK OPTIONS (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://ohrpharmaceutical.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)"/>
</link:linkbase>

↑Top
Filing Submission 0001387131-13-004795   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Thu., May 2, 8:34:32.1am ET